Erasca, Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study
The companies will evaluate ERAS-0015 with PRMT5 inhibitor navlimetostat in a clinical study involving MTAP-deleted pancreatic cancer.
The companies will evaluate ERAS-0015 with PRMT5 inhibitor navlimetostat in a clinical study involving MTAP-deleted pancreatic cancer.